Aclaris Therapeutics, Inc.
ACRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $18,720 | $31,249 | $29,752 | $6,761 |
| % Growth | -40.1% | 5% | 340.1% | – |
| Cost of Goods Sold | $2,792 | $18,081 | $11,960 | $4,713 |
| Gross Profit | $15,928 | $13,168 | $17,792 | $2,048 |
| % Margin | 85.1% | 42.1% | 59.8% | 30.3% |
| R&D Expenses | $33,586 | $98,384 | $77,813 | $43,813 |
| G&A Expenses | $22,203 | $31,098 | $25,133 | $23,619 |
| SG&A Expenses | $22,203 | $31,098 | $25,133 | $23,619 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $102,071 | -$18,957 | $4,700 | $24,339 |
| Operating Expenses | $157,860 | $110,525 | $107,646 | $91,771 |
| Operating Income | -$141,932 | -$97,357 | -$89,854 | -$89,723 |
| % Margin | -758.2% | -311.6% | -302% | -1,327.1% |
| Other Income/Exp. Net | $9,867 | $8,509 | $2,946 | -$1,142 |
| Pre-Tax Income | -$132,065 | -$88,848 | -$86,908 | -$90,865 |
| Tax Expense | $0 | -$367 | $0 | $0 |
| Net Income | -$132,065 | -$88,481 | -$86,908 | -$90,865 |
| % Margin | -705.5% | -283.1% | -292.1% | -1,344% |
| EPS | -1.71 | -1.27 | -1.33 | -1.6 |
| % Growth | -34.6% | 4.5% | 16.9% | – |
| EPS Diluted | -1.71 | -1.27 | -1.33 | -1.6 |
| Weighted Avg Shares Out | 77,297 | 69,809 | 65,214 | 56,731 |
| Weighted Avg Shares Out Dil | 77,297 | 69,809 | 65,214 | 56,731 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,953 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $807 | $863 | $797 | $923 |
| EBITDA | -$51,720 | -$115,451 | -$84,357 | -$64,461 |
| % Margin | -276.3% | -369.5% | -283.5% | -953.4% |